TABLE 1.
Summary of subjectsa
| Parameter | Value for subjects with indicated diagnosis |
||
|---|---|---|---|
| HAM/TSP | HC | NC | |
| No. of subjects | 47 | 15 | 18 |
| Sex (male/female) | 12/35 | 6/9 | 10/8 |
| Age (yrs)b | 62.8 ± 11.7c | 69.9 ± 11.4 | 49.8 ± 19.5 |
| Anti-HTLV-1 antibody in serumd | |||
| Log2 titer by PA | 14.0 ± 2.0 | 10.2 ± 2.5 | ND |
| Log10 S/CO by CLIA | 2.07 ± 0.12 | 1.97 ± 0.16 | ND |
| Log10 COI by CLEIA | 2.1 ± 0.3 | 1.4 ± 0.1 | ND |
| Anti-HTLV-1 antibody in CSFd | |||
| Log2 titer by PA | 6.7 ± 2.5 | 2.4 ± 0.5 | ND |
| Log10 S/CO by CLIA | 1.36 ± 0.41 | 0.43 ± 0.18 | ND |
| Log10 COI by CLEIA | 0.4 ± 0.6 | −0.7 ± 0.1 | ND |
| HTLV-1 PVL (copies/104 PBMCs)e | 1,138.5 ± 972.9 | 162.9 ± 129.4 | ND |
The cutoff points for serum were a titer of 16×, S/CO of 1.0, and COI of 1.0 for PA, CLIA, and CLEIA, respectively. Those for CSF were a titer of 4×, S/CO of 1.0, and COI of 1.0 for PA, CLIA, and CLEIA, respectively. The cutoff points in CLIA and CLEIA for CSF were adopted from those in serum and were commonly used because cutoff points for CSF had not been determined. Diagnosis of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) was made according to WHO diagnostic criteria. Seropositive subjects who did not satisfy the diagnostic criteria were diagnosed as HTLV-1 carriers (HCs). Seronegative subjects were diagnosed as negative controls (NCs). ND, not detected.
There was a significant difference in age among the three groups by one-way ANOVA (P < 0.01).
The values are expressed as means ± standard deviations.
Anti-HTLV-1 antibodies were logarithmically transformed from raw data by each assay.
There was a significant difference in PVL between HAM/TSP patients and HCs by the Mann-Whitney U test (P = 0.02).